A 58-year-old woman with a 10-year history of type 2 diabetes is on metformin 1000 mg BD and has an HbA₁c of 8.2%. She has no contraindications to any drug class. Her fasting glucose is 156 mg/dL, and she has mild obesity (BMI 29 kg/m²). What is the drug of choice to add as second-line therapy?

Explanation

## Second-Line Therapy in Type 2 Diabetes: SGLT2 Inhibitors **Key Point:** Current guidelines (ADA 2023, EASD 2023) prioritize SGLT2 inhibitors or GLP-1 receptor agonists as second-line agents in type 2 DM, especially in patients with obesity, cardiovascular disease, or chronic kidney disease. Sulfonylureas are no longer preferred due to hypoglycemia risk and weight gain. **High-Yield:** SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) are now preferred over sulfonylureas because they: 1. **Reduce cardiovascular mortality** (proven in EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI 58) 2. **Reduce hospitalization for heart failure** (even in non-diabetic HF) 3. **Slow CKD progression** (renal protective effect) 4. **Promote weight loss** (3–4 kg on average) 5. **Improve blood pressure** (modest reduction) 6. **Low hypoglycemia risk** when used with metformin alone **Clinical Pearl:** This patient is ideal for SGLT2i because: - Mild obesity (BMI 29) → weight loss benefit - No CKD contraindications mentioned → renal protection - No acute illness → no euDKA risk - Adequate glycemic control on metformin monotherapy (HbA₁c 8.2%, not severely elevated) ### Comparison: Second-Line Agents in Type 2 DM | Agent Class | Mechanism | HbA₁c Reduction | Weight Change | Hypoglycemia Risk | CV/Renal Benefit | Preferred Now? | |---|---|---|---|---|---|---| | **SGLT2i** (empagliflozin) | Urinary glucose excretion | 1.0–1.5% | −3 to −4 kg | Very low | **Yes (CV, renal)** | **YES** | | **GLP-1 RA** (semaglutide) | GLP-1 receptor agonism | 1.5–2.0% | −4 to −6 kg | Very low | **Yes (CV)** | **YES** | | **Sulfonylurea** (gliclazide) | β-cell stimulation | 1.0–2.0% | +2 to +3 kg | **High** | **No** | **NO** | | **Acarbose** | α-glucosidase inhibition | 0.5–1.0% | Neutral | Very low | **No** | **Rarely** | | **Insulin** | Exogenous insulin | 1.5–2.5% | +2 to +4 kg | **High** | **No** | **Third-line** | **Mnemonic:** SGLT2i = **S**odium-**G**lucose co-transporter **2** inhibitor = **Slows** glucose reabsorption in kidney → **Glucose** wasting in urine → **L**ower glucose + **T**herapeutic benefit (CV, renal, weight) **Warning:** ~~Sulfonylureas are no longer first-line second agents~~ — they increase hypoglycemia risk and cause weight gain. Insulin is reserved for third-line or advanced glycemic failure. **Tip:** In NEET PG 2024 exams, if the stem shows type 2 DM on metformin with: - Obesity or overweight → **SGLT2i or GLP-1 RA** - CKD or albuminuria → **SGLT2i** - High CV risk → **SGLT2i or GLP-1 RA** - Severe hyperglycemia (HbA₁c > 9%) → **GLP-1 RA** (stronger HbA₁c reduction) [cite:ADA Standards of Care 2023; EASD Consensus 2023; Harrison 21e Ch 417]